Fundraising Fox
ReBio
3 known investors
Find your way into ReBio
Sign up to see every warm intro you have to ReBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ReBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
Founders & leadership
RR
Roi RazChief Executive OfficerPreviously chief financial officer at Trigone Pharma and senior director of investor relations at Moderna, following work as a pharma and biotech equity analyst at AtonRâ Partners. He earlier managed biotech portfolios at Adamas Capital Management/Mascall Management and spent six years at Barak Capital as an investment analyst and portfolio manager.
Investors · 3
In the news
Frequently asked questions
- What does ReBio do?
- ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
- Who are ReBio's investors?
- ReBio's investors include Kinled Holding, SICTIC, WI Harper Group.